vs
MEDALLION FINANCIAL CORP（MFIN）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是MEDALLION FINANCIAL CORP的1.8倍（$127.1M vs $70.6M），MEDALLION FINANCIAL CORP同比增速更快（25.4% vs 17.1%），过去两年再鼎医药的营收复合增速更高（20.8% vs 15.0%）
Mahindra & Mahindra金融服务有限公司（MMFSL）是一家印度农村非银行金融公司，总部位于孟买。该公司是印度头部拖拉机融资机构之一，在印度全国拥有超过一千家分支机构
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
MFIN vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.8倍
$70.6M
营收增速更快
MFIN
高出8.3%
17.1%
两年增速更快
ZLAB
近两年复合增速
15.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $70.6M | $127.1M |
| 净利润 | $12.2M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 29.3% | -54.6% |
| 净利率 | 17.3% | — |
| 营收同比 | 25.4% | 17.1% |
| 净利润同比 | 20.3% | — |
| 每股收益（稀释后） | $0.50 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MFINZLAB
| Q4 25 | $70.6M | $127.1M | ||
| Q3 25 | $58.7M | $115.4M | ||
| Q2 25 | $62.6M | $109.1M | ||
| Q1 25 | $63.0M | $105.7M | ||
| Q4 24 | $56.3M | $108.5M | ||
| Q3 24 | $53.3M | $101.8M | ||
| Q2 24 | $51.0M | $100.1M | ||
| Q1 24 | $53.3M | $87.1M |
净利润MFINZLAB
| Q4 25 | $12.2M | — | ||
| Q3 25 | $7.8M | $-36.0M | ||
| Q2 25 | $11.1M | $-40.7M | ||
| Q1 25 | $12.0M | $-48.4M | ||
| Q4 24 | $10.1M | — | ||
| Q3 24 | $8.6M | $-41.7M | ||
| Q2 24 | $7.1M | $-80.3M | ||
| Q1 24 | $10.0M | $-53.5M |
毛利率MFINZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率MFINZLAB
| Q4 25 | 29.3% | -54.6% | ||
| Q3 25 | 33.2% | -42.3% | ||
| Q2 25 | 31.1% | -50.3% | ||
| Q1 25 | 32.1% | -53.3% | ||
| Q4 24 | 32.8% | -62.6% | ||
| Q3 24 | 26.6% | -66.6% | ||
| Q2 24 | 24.3% | -76.0% | ||
| Q1 24 | 33.6% | -80.7% |
净利率MFINZLAB
| Q4 25 | 17.3% | — | ||
| Q3 25 | 13.2% | -31.2% | ||
| Q2 25 | 17.7% | -37.3% | ||
| Q1 25 | 19.1% | -45.8% | ||
| Q4 24 | 18.0% | — | ||
| Q3 24 | 16.1% | -40.9% | ||
| Q2 24 | 13.9% | -80.2% | ||
| Q1 24 | 18.8% | -61.4% |
每股收益（稀释后）MFINZLAB
| Q4 25 | $0.50 | $-0.05 | ||
| Q3 25 | $0.32 | $-0.03 | ||
| Q2 25 | $0.46 | $-0.04 | ||
| Q1 25 | $0.50 | $-0.04 | ||
| Q4 24 | $0.43 | $-0.09 | ||
| Q3 24 | $0.37 | $-0.04 | ||
| Q2 24 | $0.30 | $-0.08 | ||
| Q1 24 | $0.42 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $136.3M | $689.6M |
| 总债务越低越好 | $216.0M | — |
| 股东权益账面价值 | $408.6M | $715.5M |
| 总资产 | $3.0B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.53× | — |
8季度趋势，按日历期对齐
现金及短期投资MFINZLAB
| Q4 25 | $136.3M | $689.6M | ||
| Q3 25 | $72.5M | $717.2M | ||
| Q2 25 | $110.4M | $732.2M | ||
| Q1 25 | $131.5M | $757.3M | ||
| Q4 24 | $98.2M | $779.7M | ||
| Q3 24 | $120.6M | $616.1M | ||
| Q2 24 | $87.7M | $630.0M | ||
| Q1 24 | $54.8M | $650.8M |
总债务MFINZLAB
| Q4 25 | $216.0M | — | ||
| Q3 25 | $215.7M | — | ||
| Q2 25 | $199.9M | — | ||
| Q1 25 | $199.7M | — | ||
| Q4 24 | $232.2M | — | ||
| Q3 24 | $232.0M | — | ||
| Q2 24 | $230.8M | — | ||
| Q1 24 | $225.6M | — |
股东权益MFINZLAB
| Q4 25 | $408.6M | $715.5M | ||
| Q3 25 | $397.4M | $759.9M | ||
| Q2 25 | $389.9M | $791.7M | ||
| Q1 25 | $380.2M | $810.8M | ||
| Q4 24 | $370.2M | $840.9M | ||
| Q3 24 | $362.4M | $667.7M | ||
| Q2 24 | $354.0M | $704.2M | ||
| Q1 24 | $349.0M | $762.2M |
总资产MFINZLAB
| Q4 25 | $3.0B | $1.2B | ||
| Q3 25 | $2.9B | $1.2B | ||
| Q2 25 | $2.9B | $1.2B | ||
| Q1 25 | $2.8B | $1.2B | ||
| Q4 24 | $2.9B | $1.2B | ||
| Q3 24 | $2.9B | $985.3M | ||
| Q2 24 | $2.8B | $987.4M | ||
| Q1 24 | $2.6B | $988.4M |
负债/权益比MFINZLAB
| Q4 25 | 0.53× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 0.53× | — | ||
| Q4 24 | 0.63× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.65× | — | ||
| Q1 24 | 0.65× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $126.3M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 10.35× | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流MFINZLAB
| Q4 25 | $126.3M | $-26.0M | ||
| Q3 25 | $67.0M | $-32.0M | ||
| Q2 25 | $-10.7M | $-31.0M | ||
| Q1 25 | $36.3M | $-61.7M | ||
| Q4 24 | $108.7M | $-55.8M | ||
| Q3 24 | $24.6M | $-26.8M | ||
| Q2 24 | $27.6M | $-42.2M | ||
| Q1 24 | $32.3M | $-90.1M |
自由现金流MFINZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | — | $-42.9M | ||
| Q1 24 | — | $-91.1M |
自由现金流率MFINZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -42.9% | ||
| Q1 24 | — | -104.5% |
资本支出强度MFINZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 1.1% |
现金转化率MFINZLAB
| Q4 25 | 10.35× | — | ||
| Q3 25 | 8.63× | — | ||
| Q2 25 | -0.97× | — | ||
| Q1 25 | 3.02× | — | ||
| Q4 24 | 10.72× | — | ||
| Q3 24 | 2.86× | — | ||
| Q2 24 | 3.89× | — | ||
| Q1 24 | 3.22× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MFIN
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
